Axial β’ 7 implied HN points β’ 03 Mar 24
- Human Immunology Biosciences (HI-Bio) is a clinical-stage biotech company focused on precision medicines for immune-mediated diseases, with the aim to target specific cellular drivers of disease with therapeutics.
- HI-Bio's assets include felzartamab and HIB210, targeting dysfunctional plasma cells and other immune system components to potentially provide more effective treatments for diseases like membranous nephropathy and IgA nephropathy.
- The company utilizes a platform that integrates human genetics, immunophenotyping, data sciences, and therapeutic engineering to advance its clinical pipeline in understanding and addressing immune-mediated diseases.